
ODTX Stock Forecast & Price Target
ODTX Analyst Ratings
Bulls say
Odyssey Therapeutics is developing innovative medicines targeting important signaling pathways in the innate immune system, with lead program OD-001 showing efficacy and safety in ulcerative colitis (UC) in Phase 1. The company's pipeline also includes candidates targeting other key signaling nodes, offering pipeline diversification and potential for expanded indications. Limited value has yet been attributed to Odyssey's pipeline, and its differentiated approach and potential for combination therapies make it an attractive investment with long-term growth potential.
Bears say
Odyssey Therapeutics is a clinical-stage biopharmaceutical company with high-risk investments in the development of therapies for autoimmune and inflammatory diseases. Failed or delayed trials, typical risks for a company at this stage of maturity, may negatively affect ODTX's stock and balance sheet, with additional risks including maintaining sufficient financial resources, protecting intellectual property, and competition in the market. The limited float and low trading volume of the stock may exacerbate volatility, and the upcoming IPO expiration may drive enhanced volatility. While ODTX's lead candidate, OD-001, is targeting a large market for inflammatory bowel disease, combination treatments and oral small molecules may be well-positioned in the market. The company's other programs targeting TNFR2, IRAK4, and IRF5 have promising potential, but their success is not guaranteed. Additionally, ODTX maintains a number of pending patent applications and intellectual property rights, with potential patent expirations in 2044 to 2045.
This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ODTX Analyst Forecast & Price Prediction
Start investing in ODTX
Order type
Buy in
Order amount
Est. shares
0 shares